Established in 2006, Fina Biosolutions was founded to assist emerging market vaccine producers in acquiring the expertise to develop cost-effective protein polysaccharide conjugates for vaccines. FinaBio has evolved into a leading provider of laboratory and consultancy services for conjugate vaccines within the Biotech and Vaccine industry worldwide. Situated in Maryland's prominent biotechnology hub, in close proximity to the US National Institutes of Health (NIH), Food and Drug Administration (FDA), and numerous global biopharmaceutical firms, we boast a fully-equipped laboratory for molecular biology, protein expression, conjugation, and conjugate vaccine characterization.